The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.

Full Abstract

Patients with type 2 diabetes, approximately 85% of whom are overweight or obese, often have an increased incidence of cardiovascular disease (CVD) risk factors such as hypertension and dyslipidemia. Both type 2 diabetes and obesity are independent risk factors for CVD. Unfortunately, many therapies aimed at maintaining and improving glucose control are associated with weight gain. Among the older antidiabetes agents, most, including the insulin secretagogues and sensitizers, can lead to weight gain, except for metformin, which is weight-neutral. Among the newer agents, the dipeptidyl peptidase-4 inhibitors generally are weight-neutral in addition to lowering glucose, while the glucagon-like peptide-1 receptor agonists lead to weight reduction. Patients with type 2 diabetes are at an increased risk for both diabetes- and CV-related outcomes, and weight reduction is an important component of diabetes management. Weight gain in patients with type 2 diabetes can contribute to patient frustration and may negatively impact their compliance to therapeutic regimens. The selection of antidiabetes agents that not only improve glucose control but reduce or have a neutral effect on weight with beneficial effects on lipids are ideal options for managing patients with type 2 diabetes.

Author information

Author/s: Pi-Sunyer, F Xavier (FX);

Affiliation: Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA. fxp1(-atsign-)columbia.edu

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: Postgraduate medicine (Postgrad Med), published in United States. (Language: eng)

Reference: 2009-Sep; vol 121 (issue 5) : pp 94-107

Dates: Created 2009/10/12; Completed 2009/11/04;

PMID: 19820278, status: MEDLINE (last retrieval date: 11/4/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Motivation
Obesity - epidemiology; prevention & control
Patient Compliance
Peptides - therapeutic use
Risk Management
Self Care - psychology
Venoms - therapeutic use
Weight Gain - drug effects

Associated Chemicals: Hypoglycemic Agents (0) ; Incretins (0) ; Peptides (0) ; Venoms (0) ; exenatide (141732-76-5) ; Glucagon-Like Peptide 1 (89750-14-1)

These are the highest related articles currently in the database: